{
    "nct_id": "NCT03618381",
    "official_title": "Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
    "inclusion_criteria": "* First 2 subjects enrolled and treated in both Arm A and Arm B: age ≥ 15 and ≤ 30 years\n* Subsequent subjects: age ≥ 1 and ≤30years\n* Histologically diagnosed malignant, non-CNS solid tumor expressing EGFR\n* Evidence of refractory or recurrent disease\n* Able to tolerate apheresis or has apheresis product available for use in manufacturing\n* Life expectancy ≥ 8 weeks\n* Lansky or Karnofsky score ≥ 50\n* Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy\n* If no apheresis product or T cell product is available,≥ 7 days post last chemotherapy/biologic therapy administration\n* If no apheresis product or T cell product is available,≥ 3 half lives or 30 days, whichever is shorter, post last dose of anti-tumor antibody therapy (including check point inhibitor)\n* Prior genetically modified cell therapy is allowed if not detectable at enrollment.\n* If no apheresis product or T cell product is available,≥ 6 weeks post last dose of myeloablative therapy and allogeneic or autologous stem cell transplant\n* Subjects who receive autologous stem cell infusion following non-myeloablative therapy are eligible once all other eligibility requirements are met\n* If no apheresis product or T cell product is available,≥ 7 days post last systemic corticosteroid therapy (physiologic replacement dosing is allowed)\n* If no apheresis product or T cell product is available, subjects with neuroblastoma must be ≥ 12 weeks from I131 MIBG therapy.\n* Adequate organ function\n* Adequate laboratory values\n* Patients of childbearing potential must agree to use highly effective contraception\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 30 Years",
    "exclusion_criteria": "* Presence of active malignancy other than primary malignant solid tumor diagnosis\n* Current relevant CNS pathology\n* Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment\n* Presence of active severe infection\n* Presence of primary immunodeficiency syndrome\n* Receiving external beam radiation therapy at time of enrollment\n* Receiving any anti-cancer agents or chemotherapy\n* Pregnant or breastfeeding\n* Unwilling to provide consent/assent for participation in the study and 15 year follow up period\n* Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol",
    "miscellaneous_criteria": ""
}